One of the elements anticipated to fuel market growth during the forecast period is the expanding availability of allergen immunotherapy treatments. Alusta, a subcutaneous allergen immunotherapy (SCIT) treatment for various allergies involving rhinitis, conjunctivitis, rhinoconjunctivitis, or asthma, is now available in Spain and Italy, according to Stallergenes Greer, one of the world's leading providers of allergy immunotherapy, which was announced in June 2021. Additionally, during the anticipated period, rising air pollution and climate change are anticipated to drive market expansion.
The market for treating Allergic Rhinitis globally is anticipated to reach US$ 14,916.9 million in 2022 and is projected to grow at a CAGR of 4.1% from 2022 to 2030.
Key Companies in the Allergic Rhinitis Treatment Industry:
Merck & Co., Inc.
The three primary business sectors of Merck KGaA are life sciences, performance materials, and healthcare. Researchers in academia and applied disciplines, such as the biopharmaceutical business, are supplied with laboratory supplies and equipment by the life sciences section. Established in 1891. German headquarters in Darmstadt. A legally binding deal has been struck by Merck to buy the chemical division of Mecaro Co. Ltd. (Mecaro), a publicly traded Korean manufacturer of heater blocks and chemical precursors for semiconductors
AstraZeneca, GSK plc
AstraZeneca was created in 1999 through the union of the Swedish company Astra with the British company Zeneca Group. The company sells branded medications in a number of important therapeutic categories, including those for gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Nearly one-third of its sales originate from the United States, which is one of the largest foreign markets. Located in England, in the United Kingdom. CinCor Pharma will be acquired by AstraZeneca to bolster its cardiorenal pipeline.
Johnson & Johnson Services, Inc
Johnson & Johnson Innovation's JJDC oversaw the Johnson & Johnson Development venture capital fund. The fund made investments in the United States and was based in New Brunswick, New Jersey. It focused on the pharmaceutical, biotechnology, and life science industries as well as medical equipment and supplies. Built in 1998. Admin centre in the U.S. There have been 25 investments and 47 acquisitions by Johnson & Johnson. Over $ 104.54 billion has been spent by the company on acquisitions. Johnson & Johnson has made investments in a variety of industries, including healthcare IT, platforms and tools for the life sciences, and disorders of the heart and vascular system.